Payment overview · 2025
General Payments
$19.57
1 reported records · 1 companies
Healthcare provider profile · identity verified
Raul Octaviani, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SPRINGFIELD, MA · NPI 1831204890
Verified facts
What the public records show
CMS Open Payments records show Raul Octaviani, M.D. received $19.57 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.57 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $19.57 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 649 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 439 | 105 |
| Furosemide | Furosemide | 420 | 85 |
| Lisinopril | Lisinopril | 416 | 108 |
| Gabapentin | Gabapentin | 389 | 75 |
| Losartan Potassium | Losartan Potassium | 388 | 100 |
| Omeprazole | Omeprazole | 371 | 88 |
| Potassium Chloride | Potassium Chloride | 354 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 317 | 89 |
| Eliquis | Apixaban | 277 | 47 |
| Metformin Hcl | Metformin Hcl | 227 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 225 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 52 |
| Carvedilol | Carvedilol | 215 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 192 | 41 |
| Spironolactone | Spironolactone | 179 | 33 |
| Simvastatin | Simvastatin | 163 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 35 |
| Tramadol Hcl | Tramadol Hcl | 133 | 28 |
| Famotidine | Famotidine | 124 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 17 |
| Jardiance | Empagliflozin | 104 | 21 |
| Donepezil Hcl | Donepezil Hcl | 103 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 37 |
| Montelukast Sodium | Montelukast Sodium | 100 | 18 |
| Finasteride | Finasteride | 97 | 14 |
| Jantoven | Warfarin Sodium | 91 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 18 |
| Allopurinol | Allopurinol | 85 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 15 |
| Mirtazapine | Mirtazapine | 75 | 13 |
| Azithromycin | Azithromycin | 72 | 56 |
| Meloxicam | Meloxicam | 72 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 12 |
| Prednisone | Prednisone | 67 | 34 |
| Trazodone Hcl | Trazodone Hcl | 67 | 18 |
| Metformin Hcl Er | Metformin Hcl | 66 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 17 |
| Fentanyl | Fentanyl | 64 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 16 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 30 |
| Propranolol Hcl | Propranolol Hcl | 56 | 11 |
| Xarelto | Rivaroxaban | 56 | 13 |
| Warfarin Sodium | Warfarin Sodium | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 53 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | suppressed |
| Atenolol | Atenolol | 51 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 15 |
| Sertraline Hcl | Sertraline Hcl | 50 | 17 |
| Fenofibrate | Fenofibrate | 49 | 11 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Celecoxib | Celecoxib | 47 | 13 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Chlorthalidone | Chlorthalidone | 46 | 15 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 45 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Ozempic | Semaglutide | 43 | suppressed |
| Lorazepam | Lorazepam | 42 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 41 | suppressed |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Glipizide | Glipizide | 41 | suppressed |
| Digoxin | Digoxin | 38 | suppressed |
| Gemfibrozil | Gemfibrozil | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 37 | 27 |
| Latanoprost | Latanoprost | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Nystatin | Nystatin | 30 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 22 |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $19.57 · 1 records | ABBVIE INC. | QULIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error